Bank of America’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-212
| Closed | -$48 | – | 8660 |
|
|
2024
Q4 | $48 | Sell |
212
-493
| -70% | -$592 | ﹤0.01% | 7874 |
|
|
2024
Q3 | $1.52K | Sell |
705
-17,419
| -96% | -$62.6K | ﹤0.01% | 7173 |
|
|
2024
Q2 | $93.5K | Sell |
18,124
-15,618
| -46% | -$82.1K | ﹤0.01% | 6275 |
|
|
2024
Q1 | $181K | Buy |
33,742
+23,721
| +237% | +$164K | ﹤0.01% | 5932 |
|
|
2023
Q4 | $78.1K | Buy |
10,021
+9,953
| +14,637% | +$34.1K | ﹤0.01% | 6475 |
|
|
2023
Q3 | $269 | Sell |
68
-1
| -1% | -$4 | ﹤0.01% | 7379 |
|
|
2023
Q2 | $218 | Sell |
69
-1,046
| -94% | -$3.36K | ﹤0.01% | 7380 |
|
|
2023
Q1 | $2.98K | Sell |
1,115
-34
| -3% | -$132 | ﹤0.01% | 7166 |
|
|
2022
Q4 | $4.13K | Sell |
1,149
-7
| -0.6% | -$30 | ﹤0.01% | 7093 |
|
|
2022
Q3 | $7K | Sell |
1,156
-1,295
| -53% | -$10.5K | ﹤0.01% | 7319 |
|
|
2022
Q2 | $24K | Sell |
2,451
-355
| -13% | -$3.32K | ﹤0.01% | 7128 |
|
|
2022
Q1 | $34K | Sell |
2,806
-1,444
| -34% | -$25.8K | ﹤0.01% | 7326 |
|
|
2021
Q4 | $139K | Buy |
4,250
+1,136
| +36% | +$46K | ﹤0.01% | 6704 |
|
|
2021
Q3 | $139K | Sell |
3,114
-187
| -6% | -$9.13K | ﹤0.01% | 6534 |
|
|
2021
Q2 | $180K | Sell |
3,301
-828
| -20% | -$49K | ﹤0.01% | 6162 |
|
|
2021
Q1 | $309K | Buy |
4,129
+2,718
| +193% | +$282K | ﹤0.01% | 5729 |
|
|
2020
Q4 | $153K | Sell |
1,411
-4,138
| -75% | -$378K | ﹤0.01% | 5764 |
|
|
2020
Q3 | $491K | Buy |
5,549
+3,660
| +194% | +$416K | ﹤0.01% | 4736 |
|
|
2020
Q2 | $202K | Sell |
1,889
-261
| -12% | -$23.4K | ﹤0.01% | 5239 |
|
|
2020
Q1 | $128K | Buy |
2,150
+642
| +43% | +$43.6K | ﹤0.01% | 5384 |
|
|
2019
Q4 | $104K | Buy |
1,508
+136
| +10% | +$8.25K | ﹤0.01% | 5986 |
|
|
2019
Q3 | $142K | Buy |
1,372
+569
| +71% | +$53.7K | ﹤0.01% | 5864 |
|
|
2019
Q2 | $75K | Buy |
803
+50
| +7% | +$3.48K | ﹤0.01% | 6128 |
|
|
2019
Q1 | $69K | Sell |
753
-987
| -57% | -$68.7K | ﹤0.01% | 6060 |
|
|
2018
Q4 | $98K | Buy |
1,740
+1,171
| +206% | +$89K | ﹤0.01% | 5934 |
|
|
2018
Q3 | $68K | Buy |
569
+200
| +54% | +$23.2K | ﹤0.01% | 6066 |
|
|
2018
Q2 | $38K | Buy |
369
+248
| +205% | +$30.7K | ﹤0.01% | 6274 |
|
|
2018
Q1 | $16K | Sell |
121
-28
| -19% | -$3.06K | ﹤0.01% | 6465 |
|
|
2017
Q4 | $14K | Buy |
149
+77
| +107% | +$10.3K | ﹤0.01% | 6528 |
|
|
2017
Q3 | $11K | Buy |
72
+41
| +132% | +$7.71K | ﹤0.01% | 6518 |
|
|
2017
Q2 | $5K | Sell |
31
-51
| -62% | -$8.01K | ﹤0.01% | 6603 |
|
|
2017
Q1 | $13K | Buy |
82
+18
| +28% | +$2.2K | ﹤0.01% | 6469 |
|
|
2016
Q4 | $8K | Buy |
+64
| New | +$8.97K | ﹤0.01% | 6611 |
|
Other funds holding SYRS
BBA
1CM
XT
Bank of America's SYRS Position: Q1 2025 in Review
Bank of America sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 212 shares — an estimated $48 sold.
Bank of America first reported a position in SYRS in Q4 2016 and held it in 33 quarters. The position peaked at $491K in Q3 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- Bank of America reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Bank of America sold 212 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $48.
- Bank of America first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 33 quarters.
- Bank of America's Syros Pharmaceuticals, Inc. Common Stock position peaked at $491K in Q3 2020.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on Bank of America's 13F filing for Q1 2025, filed 15 May 2025.